BLNK and neoplasm: This paradigm shift raises critical questions regarding the optimal sequencing of treatments, the potential impact of inotuzumab on CAR-T efficacy and expansion, and how best to balance toxicity with therapeutic benefit—especially considering factors like pre-infusion BCA and tumor burden (11, 25).